Drug or treatment

Camrelizumab clinical trials

• 66Clinical trials
• 1New in 30 days
• 2Countries

Newest trials

All recruiting trials (66)

• Ivarmacitinib with Camrelizumab and Fruquintinib in advanced colorectal cancer after prior therapies

  This trial tests whether combining ivarmacitinib with camrelizumab and fruquintinib can help patients with metastatic colorectal cancer who have progressed after multiple treatments.

  Recruiting Phase 2 Renmin Hospital of Wuhan University · Wuhan, Hubei · NCT07896096

• Interferon-gamma plus camrelizumab with chemotherapy before surgery for locally advanced esophageal squamous cell carcinoma

  This trial tests whether giving interferon-gamma with camrelizumab and chemotherapy before surgery helps patients with locally advanced esophageal squamous cell carcinoma.

  Recruiting at 2 sites Phase 2 Hefei Cancer Hospital of the Chinese Academy of Sciences · Hefei, Anhui and 1 other locations · NCT07787273

• Camrelizumab with Famitinib for rare head and neck cancers

  This trial tests whether combining camrelizumab with famitinib can help adults with unresectable or metastatic soft tissue sarcoma, malignant melanoma, adenoid cystic carcinoma, or certain salivary gland cancers who have not tried a PD-1 inhibitor before.

  Recruiting Phase 1/2 Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Shanghai, Shanghai Municipality · NCT07662681

• Camrelizumab with chemoradiotherapy to preserve organs in locally advanced resectable ESCC

  This study tests whether adding camrelizumab to chemoradiotherapy can help preserve the esophagus in adults with locally advanced, resectable esophageal squamous cell carcinoma.

  Recruiting Phase 2 The First Affiliated Hospital of Henan University of Science and Technology · Luoyang, Henan · NCT07622797

• Cryoablation plus anti-PD-1 therapy for advanced soft tissue sarcoma

  This study tests whether freezing tumors and giving camrelizumab can help people with advanced soft tissue sarcoma after standard treatments have failed.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07602049

• VRT106 plus camrelizumab and apatinib for advanced HCC in patients who have tried prior ICIs

  This study tests VRT106, with camrelizumab and apatinib, to see if it helps people with advanced hepatocellular carcinoma who have already had prior immune checkpoint inhibitors fail.

  Recruiting Phase 2/3 Guangzhou Virotech Pharmaceutical Co., Ltd. · Guangzhou, Guangdong · NCT07589244

• Short-course definitive chemoradiotherapy with camrelizumab for locally advanced unresectable esophageal squamous cell carcinoma

  This trial sees if adding camrelizumab to short-course chemoradiotherapy—given either during treatment and continued afterwards or given only as maintenance afterwards—improves tumor response and survival for adults with locally advanced unresectable esophageal squamous cell carcinoma.

  Recruiting Phase 2 Jiangsu Cancer Institute & Hospital · Nanjing, Jiangsu · NCT07530094

• Camrelizumab with long-course chemoradiotherapy before surgery for locally advanced low rectal cancer (pMMR/MSS)

  This trial tests whether giving camrelizumab before and after long-course chemoradiotherapy helps people with locally advanced, pMMR/MSS low rectal cancer achieve a higher complete response and preserve the rectum.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07527026

• Camrelizumab, chemotherapy and Ivarmacitinib before surgery for resectable esophageal squamous cell carcinoma

  This trial tests whether giving camrelizumab with chemotherapy and the JAK inhibitor Ivarmacitinib before surgery can improve outcomes for patients with locally advanced esophageal squamous cell carcinoma that can be removed by operation.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, China · NCT07505186

• Y-90 microspheres with camrelizumab and/or apatinib versus Y-90 alone or cTACE for unresectable liver cancer

  This trial will test whether adding camrelizumab and/or apatinib to Y-90 microsphere treatment helps people with unresectable, non-metastatic hepatocellular carcinoma more than Y-90 alone or conventional TACE.

  Recruiting at 2 sites Phase 2 GrandPharma (China) Co., Ltd. · Beijing and 2 other locations · NCT07334483

• Camrelizumab plus apatinib with or without FOLFOX chemotherapy for advanced liver cancer

  This research will test whether adding FOLFOX chemotherapy to camrelizumab plus apatinib helps adults with advanced hepatocellular carcinoma who have not received prior systemic treatment.

  Recruiting Phase 3 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07267806

• Dalpiciclib plus camrelizumab for advanced liver cancer after prior immunotherapy

  This trial will test whether combining dalpiciclib with camrelizumab can control tumors in people with unresectable hepatocellular carcinoma whose cancer progressed after prior immune checkpoint inhibitor treatment.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07238881

• Camrelizumab plus chemotherapy as adjuvant treatment for node-positive stage IIICp cervical cancer

  This trial tests whether adding camrelizumab to chemotherapy after radical surgery helps people with PD-L1–positive, node-positive (FIGO2018 IIIC1p/IIIC2p) cervical cancer.

  Recruiting Phase 2 Women's Hospital School Of Medicine Zhejiang University · Hangzhou, Zhejiang · NCT07167160

• Apatinib and camrelizumab plus TACE before liver resection for centrally-located BCLC‑B hepatocellular carcinoma

  This trial tests whether giving apatinib and camrelizumab together with TACE before planned liver surgery can shrink tumors and improve outcomes for adults with centrally-located BCLC stage B hepatocellular carcinoma who are eligible for resection.

  Recruiting Phase 2 Tongji Hospital · Wuhan, Hubei · NCT07154082

• Hepatic arterial infusion chemotherapy with camrelizumab and rivoceranib for advanced mixed hepatocellular‑cholangiocarcinoma

  This will test whether adding camrelizumab and rivoceranib to hepatic arterial infusion chemotherapy helps people with advanced mixed hepatocellular‑cholangiocarcinoma.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07105748

• TUDCA with camrelizumab and regorafenib for advanced hepatocellular carcinoma after anti‑PD‑1/PD‑L1 plus bevacizumab

  This trial tests whether adding TUDCA to camrelizumab and regorafenib helps people with advanced hepatocellular carcinoma that got worse after anti‑PD‑1/PD‑L1 plus bevacizumab.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07100392

• Perioperative radiotherapy with SOX chemotherapy plus apatinib and camrelizumab for esophagogastric cancer

  This trial tests whether adding apatinib and camrelizumab to SOX chemotherapy and radiotherapy before and after surgery helps adults with locally advanced gastric or GEJ adenocarcinoma.

  Recruiting Phase 2 Ruijin Hospital · Shanghai, Shanghai Municipality · NCT07026149

• D-BACE plus chemotherapy and camrelizumab for resectable stage II–IIIA and potentially resectable T3–4N2 IIIB non-small cell lung cancer

  This study will see if adding D-BACE (drug-eluting bead bronchial arterial chemoembolization) to standard neoadjuvant chemotherapy and camrelizumab helps adults with resectable stage II–IIIA or potentially resectable T3–4N2 IIIB NSCLC respond better before surgery.

  Recruiting Phase 2 Guangdong Provincial People's Hospital · Guangzhou, Guangdong · NCT07016126

• Camrelizumab plus apatinib and eribulin versus physician's choice chemotherapy for advanced triple-negative breast cancer

  This trial tests whether combining camrelizumab, apatinib, and eribulin works better than your doctor's chosen chemotherapy for adults with advanced triple-negative breast cancer who have had 1–4 prior systemic treatments.

  Recruiting at 5 sites Phase 3 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong and 6 other locations · NCT06889688

• Neoadjuvant camrelizumab plus chemotherapy to preserve the esophagus in resectable esophageal squamous carcinoma

  This trial will test whether giving camrelizumab with nab-paclitaxel and cisplatin before surgery helps people with resectable esophageal squamous cancer preserve their esophagus and tolerate surgery.

  Recruiting Phase 2 Peking University Cancer Hospital & Institute · Beijing · NCT06869226

• Comparing two and three cycles of chemotherapy with immunotherapy for advanced nasopharyngeal cancer

  This study is testing whether two cycles of chemotherapy combined with immunotherapy can help people with advanced nasopharyngeal cancer just as much as three cycles, but with fewer side effects.

  Recruiting at 3 sites Phase 2 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian and 2 other locations · NCT06811844

• Camrelizumab with Rivoceranib and HAIC as conversion therapy for potentially resectable liver cancer

  This study tests whether adding hepatic arterial infusion chemotherapy to camrelizumab and rivoceranib helps shrink liver tumors enough to allow surgical removal in people with potentially resectable hepatocellular carcinoma.

  Recruiting at 2 sites Phase 2/3 Shanghai Zhongshan Hospital · Harbin, Heilongjiang and 1 other locations · NCT06796803

• New treatment for advanced gastric cancer using TAS-102, bevacizumab, and camrelizumab

  This study is testing a new combination of medications for people with advanced stomach cancer who haven't had success with other treatments to see if it can help them.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT06711471

• Comparing two chemotherapy regimens with Camrelizumab for advanced nasopharyngeal carcinoma

  This study is testing whether two different chemotherapy treatments combined with the immunotherapy drug Camrelizumab can help people with advanced nasopharyngeal cancer live longer and feel better.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong · NCT06669611

• Combination therapy for advanced liver cancer patients

  This study is testing a new combination treatment for patients with advanced liver cancer to see if it can improve their chances of survival and how well they tolerate it.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT06607107

• Neoadjuvant treatment for gBRCA-mutated HER2-negative breast cancer

  This study is testing a new treatment combination for women with a specific type of breast cancer linked to BRCA mutations to see if it can work without traditional chemotherapy.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06516289

• Combining TACE with Camrelizumab and Apatinib for Liver Cancer

  This study is testing if combining a liver cancer treatment called TACE with two drugs, camrelizumab and apatinib, can help people with advanced liver cancer live longer and feel better compared to standard treatments.

  Recruiting Phase 3 Sichuan Cancer Hospital and Research Institute · Chengdu, Sichuan · NCT06485466

• Comparing two treatment regimens for high-risk nasopharyngeal carcinoma

  This study is testing a new combination of treatments for patients with high-risk nasopharyngeal cancer to see if it works better than the standard treatment.

  Recruiting at 2 sites Phase 3 Sun Yat-sen University · Guangzhou, Guangdong and 1 other locations · NCT06438627

• Neoadjuvant therapy for borderline resectable pancreatic cancer using radiotherapy and immunotherapy

  This study is testing a new treatment combining radiation, chemotherapy, and immunotherapy for people with borderline resectable pancreatic cancer to see if it helps them have successful surgery.

  Recruiting Phase 2 Hebei Medical University Fourth Hospital · Shijiazhuang, Hebei · NCT06435260

• Combining Camrelizumab with GEMOX for treating unresectable gallbladder cancer

  This study is testing if combining a new drug called Camrelizumab with standard chemotherapy can help people with advanced gallbladder cancer live longer and feel better.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT06423170

• Combining Camrelizumab and Fluzoparib for TP-53 Mutated Endometrial Cancer

  This study is testing if combining two treatments, camrelizumab and fluzoparib, can help people with TP-53 mutated endometrial cancer that has come back or spread.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT06413992

• Combination treatment for advanced NK/T-cell lymphoma

  This study is testing a new combination treatment for people with advanced NK/T-cell lymphoma to see if it is safe and effective.

  Recruiting Phase 1/2 Beijing Tongren Hospital · Beijing, Beijing Municipality · NCT06376721

• Combining TAE+HAIC with Camrelizumab and Apatinib for Advanced Liver Cancer

  This study is testing a new combination treatment for advanced liver cancer to see if it can help patients with high tumor loads feel better and improve their outcomes.

  Recruiting Phase 2 Fujian Medical University · Fuzhou · NCT06363825

• Evaluating a new treatment combination for metastatic pancreatic cancer

  This study is testing a new combination of treatments for people with advanced pancreatic cancer to see if it works better than the standard care they usually receive.

  Recruiting at 52 sites Phase 2/3 Hutchmed · Hefei, Anhui and 51 other locations · NCT06361888

• Combining radiotherapy with camrelizumab and apatinib for liver cancer treatment

  This study is testing if a combination of radiation therapy with two medications can help shrink liver cancer tumors before surgery for patients whose cancer has spread to the portal vein.

  Recruiting Phase 2 Meng Chao Hepatobiliary Hospital of Fujian Medical University · Fuzhou, Fujian · NCT06349317

• Combining capecitabine with camrelizumab for treating specific triple-negative breast cancer

  This study is testing if combining a new drug called camrelizumab with capecitabine can help people with triple-negative breast cancer live longer and healthier after not responding fully to initial treatment.

  Recruiting Phase 3 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT06313463

• Neoadjuvant immunochemotherapy for PD-L1-negative locally advanced cervical cancer

  This study is testing a new treatment that combines chemotherapy with a drug called Camrelizumab to see if it can help people with PD-L1-negative locally advanced cervical cancer before surgery.

  Recruiting at 12 sites Phase 2 Tongji Hospital · Hefei, Anhui and 11 other locations · NCT06288360

• Combining cadonilimab and regorafenib for advanced liver cancer patients who didn't respond to previous treatment

  This study is testing if combining two drugs, cadonilimab and regorafenib, can help people with advanced liver cancer who didn't respond to earlier treatments.

  Recruiting Phase 2 Meng Chao Hepatobiliary Hospital of Fujian Medical University · Fuzhou, Fujian · NCT06280105

• Combining camrelizumab with chemotherapy for lung cancer treatment

  This study is testing if combining a new drug called camrelizumab with chemotherapy can help people with certain types of lung cancer before surgery.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT06241807

• Comparing two treatment methods for advanced liver cancer

  This study is testing two different treatment methods for advanced liver cancer to see which one helps patients feel better and live longer.

  Recruiting Phase 3 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT06172205

• Camrelizumab with chemotherapy and radiotherapy for esophageal gastric junction cancer

  This study is testing if adding a new drug called camrelizumab to chemotherapy and radiotherapy can help people with esophageal gastric junction cancer have better surgery results and live longer.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT06163729

• Fluzoparib combined with camrelizumab and temozolomide for advanced melanoma

  This study is testing a new combination of three drugs to see if it can help people with advanced melanoma that has certain genetic changes.

  Recruiting Phase 1/2 Peking University Cancer Hospital & Institute · Beijing · NCT05983237

• Combining Camrelizumab with Pemetrexed and Carboplatin for Lung Cancer Treatment

  This study is testing if a new combination of camrelizumab with two other drugs can help people in Korea with advanced lung cancer feel better and improve their treatment outcomes.

  Recruiting at 8 sites Phase 2 CrystalGenomics, Inc. · Anam and 7 other locations · NCT05841472

• Combining chemotherapy with camrelizumab for non-small cell lung cancer patients after surgery

  This study is testing if combining chemotherapy with the immunotherapy drug camrelizumab helps patients with stage IIA-IIIA non-small cell lung cancer feel better after their surgery.

  Recruiting Phase 2 Nanfang Hospital, Southern Medical University · Guandong, Guangdong · NCT05825443

• Combining Camrelizumab, Apatinib, and Temozolomide for Advanced Acral Melanoma Treatment

  This study is testing a new combination of three medications to see if it helps people with advanced acral melanoma live longer without their cancer getting worse compared to standard treatments.

  Recruiting Phase 3 Peking University Cancer Hospital & Institute · Beijing · NCT05789043

• New treatments for advanced nasopharyngeal cancer with detectable EBV DNA after chemotherapy

  This study is testing if adding two new treatments, camrelizumab or nimotuzumab, to standard chemotherapy can help people with advanced nasopharyngeal cancer who still have detectable EBV DNA after their first round of treatment.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT05772208

• Combination therapy for early breast cancer with HRR gene mutation

  This study is testing a new combination of three drugs to see if it helps people with early-stage HER2-negative breast cancer and specific gene mutations feel better before surgery.

  Recruiting Phase 2 First Affiliated Hospital, Sun Yat-Sen University · Guangzhou, Guangdong · NCT05761470

• Combining Famitinib and Camrelizumab for Treating Advanced Triple-Negative Breast Cancer

  This study is testing if combining Famitinib with Camrelizumab can help people with advanced triple-negative breast cancer do better than just using Camrelizumab with another treatment.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT05760378

• Combining Lenvatinib, TACE, and Camrelizumab for Advanced Liver Cancer Treatment

  This study is testing a new combination treatment of lenvatinib, TACE, and camrelizumab to see if it helps people with advanced liver cancer live longer compared to using lenvatinib and TACE alone.

  Recruiting Phase 3 West China Hospital · Chengdu, Sichuan · NCT05738616

• Combining camrelizumab and apatinib with chemotherapy for advanced esophageal cancer

  This study is testing a new combination of two drugs and chemotherapy to see if it helps people with advanced esophageal cancer feel better compared to standard chemotherapy.

  Recruiting Phase 2 The First Affiliated Hospital of Zhengzhou University · Zhengzhou, Henan · NCT05738434

• Combining camrelizumab with chemoradiotherapy for advanced esophageal cancer

  This study is testing if adding a new immunotherapy drug called camrelizumab to standard chemotherapy and radiation can help people with advanced esophageal cancer feel better and improve their treatment results.

  Recruiting Phase 2 Fujian Cancer Hospital · Fuzhou · NCT05624099

• Combining camrelizumab and apatinib with TACE for liver cancer treatment

  This study is testing if combining two medications with a liver cancer treatment before surgery can help people with liver cancer live longer and have fewer problems after surgery.

  Recruiting Phase 3 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT05613478

• Fluzoparib with Camrelizumab before surgery for BRCA-mutated, HER2-negative breast cancer

  This study tests whether the drug combo fluzoparib and camrelizumab can shrink BRCA-mutated, HER2-negative breast tumors before surgery in eligible patients.

  Recruiting Phase 2 Peking University People's Hospital · Beijing, Beijing Municipality · NCT05576389

• Combination therapy for high-risk acral melanoma before surgery

  This study is testing a new combination of treatments before surgery to see if it can help people with high-risk acral melanoma have better outcomes.

  Recruiting Phase 2 Peking University Cancer Hospital & Institute · Beijing, Beijing Municipality · NCT05512481

• Neoadjuvant therapy with immunotherapy for esophageal cancer

  This study is testing a new treatment combining radiation, chemotherapy, and an immunotherapy drug to see if it helps people with esophageal cancer before surgery.

  Recruiting Phase 2 Zhejiang Cancer Hospital · Hanzhou, Zhejiang and 2 other locations · NCT05507411

• Combining Camrelizumab with TCb for treating triple-negative breast cancer

  This study is testing if combining a new drug called camrelizumab with a chemotherapy treatment can help people with triple-negative breast cancer do better after surgery.

  Recruiting Phase 2 Henan Cancer Hospital · Zhengzhou, Henan · NCT05475678

• Combining camrelizumab, apatinib, and chemotherapy for treating triple negative breast cancer

  This study tests if a new combination of camrelizumab, apatinib, and chemotherapy can help shrink tumors and improve outcomes for patients with early or locally advanced triple negative breast cancer before surgery.

  Recruiting Phase 2 West China Hospital · Chengdu, Sichuan · NCT05447702

• Evaluating camrelizumab and apatinib mesylate for liver cancer treatment

  This study is testing whether a combination of two drugs, camrelizumab and apatinib mesylate, can help people with liver cancer that can't be surgically removed feel better and improve their health.

  Recruiting Meng Chao Hepatobiliary Hospital of Fujian Medical University · Fuzhou, Fujian · NCT05409482

• Combining surufatinib and camrelizumab with chemotherapy for advanced pancreatic cancer

  This study is testing a new combination of treatments for people with advanced pancreatic cancer to see if it works better than the standard options.

  Recruiting Phase 1/2 Chinese PLA General Hospital · Beijing · NCT05218889

• Combining Camrelizumab with chemotherapy for left-sided obstructive colorectal cancer

  This study tests if combining a new immunotherapy drug with chemotherapy can help people with left-sided obstructive colorectal cancer live longer and have better surgery outcomes after getting a stent.

  Recruiting Beijing Chao Yang Hospital · Beijing, Beijing Municipality · NCT05202314

• Combining camrelizumab with chemotherapy for esophageal cancer treatment

  This study is testing if combining a new immune therapy with chemotherapy can help patients with esophageal cancer feel better and live longer before and after surgery.

  Recruiting Phase 2 The First Affiliated Hospital of Zhengzhou University · Zhengzhou, Henan · NCT05182944

• Camrelizumab plus apatinib for high‑risk gestational trophoblastic neoplasia

  This trial will test whether adding camrelizumab and apatinib to chemotherapy helps women with ultra high‑risk or chemo‑refractory/relapsed high‑risk gestational trophoblastic neoplasia achieve remission.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing · NCT05139095

• Surgery combined with immunotherapy and targeted therapy for advanced liver cancer

  This study is testing whether combining surgery with two treatments, camrelizumab and apatinib, can help people with advanced liver cancer live longer and feel better.

  Recruiting Phase 2/3 Guangxi Medical University · Nanning · NCT05062837

• Combining camrelizumab with targeted radiotherapy for advanced nasopharyngeal cancer

  This study is testing if combining a new cancer drug with targeted radiation can help people with advanced nasopharyngeal cancer live longer and possibly be cured compared to just using the drug alone.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong · NCT04944914

• Combining PD-1 treatment with chemotherapy and radiotherapy for high-risk nasopharyngeal cancer

  This study is testing if adding a new immune therapy to chemotherapy and radiotherapy can help people with high-risk nasopharyngeal cancer live longer and feel better.

  Recruiting at 3 sites Phase 3 Sun Yat-sen University · Guangzhou, Guangdong and 5 other locations · NCT04453826

• Camrelizumab plus apatinib for advanced gastric and gastroesophageal junction adenocarcinoma

  This trial tests whether combining camrelizumab and apatinib can help people with advanced gastric or gastroesophageal junction cancer that progressed after first-line platinum-based therapy, especially if their tumors are PD-L1 positive.

  Recruiting Phase 3 Jiangsu HengRui Medicine Co., Ltd. · Beijing · NCT04342910

Quick answers

How many clinical trials of Camrelizumab are recruiting right now?

66, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 2 countries. The most sites are in China (65 trials), South Korea (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 41, Phase 3: 15, Phase 1/2: 4, Phase 2/3: 4. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →